Fotonen/iStock Editorial via Getty Images
AstraZeneca (NASDAQ:AZN) said Imfinzi plus Lynparza and Imfinzi alone both significantly improved progression-free survival (PFS) in advanced endometrial cancer when added to chemotherapy in a phase 3 trial.
Endometrial cancer starts in the layer of cells which form the lining (endometrium) of the uterus.
The phase 3 trial, dubbed DUO-E, evaluated 1st-line Imfinzi in combination with platinum-based chemotherapy (carboplatin and paclitaxel) followed by Imfinzi (durvalumab) with Lynparza (olaparib) or Imfinzi alone as maintenance therapy, compared to platinum-based chemotherapy alone as a treatment for patients with newly diagnosed advanced or recurrent endometrial cancer.
The British pharma giant said Imfinzi plus chemo followed by either Imfinzi plus Lynparza or Imfinzi alone as maintenance therapy both showed a statistically significant and clinically meaningful improvement in PFS versus chemo alone.
PFS is the length of time during/after treatment that a patient lives without the disease getting worse.
The company noted that overall survival (OS) data were immature at the time of the analysis but a favorable trend was seen for both treatment regimens.
“These DUO-E data demonstrate for the first time the power of combining immunotherapy and a PARP inhibitor to provide meaningful clinical improvements for patients with endometrial cancer,” said Susan Galbraith, executive vice president, Oncology R&D, AstraZeneca.
The safety and tolerability profile of Imfinzi plus chemo and of Imfinzi in combination with Lynparza was broadly consistent with that seen in previous trials.
AstraZeneca plans to discuss the data with health authorities and will present the results at a medical meeting.
More on AstraZeneca
- AstraZeneca: Think Medium-To-Long Term
- Is AstraZeneca Overvalued After Publishing Q1 2023 Financial Results?
